Home Markets Leukotriene a 4 Hydrolase Drug Review 2017

Leukotriene a 4 Hydrolase Drug Review 2017

46
SHARE

Leukotriene A 4 Hydrolase Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Leukotriene A 4 Hydrolase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Leukotriene A 4 Hydrolase pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Involved in Leukotriene A 4 Hydrolase Development are Celtaxsys Inc, Johnson & Johnson, Nippon Kayaku Co Ltd

The Leukotriene A 4 Hydrolase pipeline guide also reviews of key players involved in therapeutic development for Leukotriene A 4 Hydrolase and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.

Sample copy is available at: https://www.marketinsightsreports.com/reports/062215776/leukotriene-a-4-hydrolase-lta-4-hydrolase-or-leukotriene-a4-hydrolase-or-lta4h-or-ec-3-3-2-6-pipeline-review-h1-2017/inquiry

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leukotriene A 4 Hydrolase. The pipeline guide reviews pipeline therapeutics for Leukotriene A 4 Hydrolase by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leukotriene A 4 Hydrolase therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Leukotriene A 4 Hydrolase therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Leukotriene A 4 Hydrolase.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leukotriene A 4 Hydrolase. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leukotriene A 4 Hydrolase pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report at: https://www.marketinsightsreports.com/reports/062215776/leukotriene-a-4-hydrolase-lta-4-hydrolase-or-leukotriene-a4-hydrolase-or-lta4h-or-ec-3-3-2-6-pipeline-review-h1-2017

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) – Leukotriene A4 hydrolase (LTA4H) is an enzyme which converts leukotriene A4 to leukotriene B4 and acts as an aminopeptidase. LTB4 is a potent lipid chemoattractant involved in inflammation, immune responses, host defense against infection and PAF-induced shock.

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Cardiovascular, Respiratory, Dermatology and Hematological Disorders which include indications Pulmonary Arterial Hypertension, Acne Vulgaris, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Emphysema and Lymphedema.

The latest report Leukotriene A 4 Hydrolase – Pipeline Review, H1 2017, outlays comprehensive information on the Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

LEAVE A REPLY

Please enter your comment!
Please enter your name here